Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Univfy Expands Leadership Team with Key Hires to Support Continued Rapid Growth

Univfy
Posted on: 30 Nov 17

LOS ALTOS, Calif., Nov. 29, 2017 /PRNewswire/ -- Univfy® Inc., a predictive analytics company in the fertility space, announced today the addition of three key members to its leadership team, as it ramps up efforts to expand its predictive technology and services to in vitro fertilization (IVF) providers and patients across the country.

Kelsey Rush joins Univfy as VP of Product to lead platform strategy, and brings over 10 years of experience and deep knowledge of clinical care, digital health and pharmaceutical research, as well as her passion for improving the lives of healthcare providers and patients. Her prior leadership roles included Director of Platform Product Management at Change Healthcare and Operational Management at Oracle's Health Sciences Global Business Unit.

Kristin Shadick joins Univfy as VP of Sales to lead strategic sales initiatives and provider-patient market expansion. With a background in clinical women's reproductive health, Mrs. Shadick established expertise in the commercialization of innovative start-up technologies. Previously, she helped to grow sales at Natera, a leader in non-invasive prenatal testing and SNP microarray technology, from early-stage to post-IPO, and led Natera's IVF Reproductive Genetics Sales in the New York Tri-State Region since 2013. Prior to Natera, Mrs. Shadick led the New York state Sales and Operational team at Matria/Alere.

Kamal Gelya, M.B.A, joins Univfy as VP of Finance, overseeing business planning, financial reporting and operations. Mr. Gelya was formerly the Finance and Analytics Manager for Citrix's Workspace Services and Business Unit, where he performed strategic planning and business modeling for Service Provider and Citrix Cloud. He brings to the team more than 10 years of experience in Business Intelligence and Analytics in the technology sector.

"We're pleased to have such accomplished and talented individuals join us, as we expand our team in response to significant interest from fertility patients and providers in our Univfy platform," said Mylene Yao, co-founder and CEO of Univfy. "Univfy predictive analytics technology is the first of its kind, that combines machine learning, healthcare artificial intelligence and fintech to dramatically improve the experience of fertility patients and their access to IVF. Univfy's mission is to help more women and couples build their families, and that means building a great team to deliver."

Contact: 
Investors.info@univfy.com

About Univfy®

Progressive fertility centers across the country are using the award-winning Univfy PreIVF Report and the Univfy-Powered IVF Refund Program to make IVF a more affordable and realistic option for more fertility patients.

One in eight U.S. couples have infertility. IVF is the most effective fertility treatment for most couples, but the high costs and uncertainty of outcomes keep many couples from having a baby from IVF. Over 60% of fertility patients do not have full insurance coverage for IVF. Patients typically pay more than $10-20K for one IVF treatment and over a third of them may need two or more treatments.

Univfy empowers women and their partners to make confident decisions about fertility treatment by dramatically improving the patient's experience, expanding affordability of having several IVF treatments and maximizing a woman's chance of having a healthy baby from IVF.

Founded by experts in reproductive medicine and machine learning from Stanford University, Univfy has established proprietary technology to develop prediction models of IVF success rates that are validated for individual IVF centers and personalized to each patient based on her health data.

About the IVF market 
Six to 7 million reproductive age couples in the US and 80-100 million couples worldwide are affected by infertility. The IVF market, valued at $9 billion in 2015, is expected to reach $17 to $27 billion by 2022 and show CAGR of 10.2% during the forecast period 2014-2022.1,2

1In Vitro Fertilization (IVF) Services Market by Cycle Type, End User - Global Opportunity Analysis and Industry Forecast, 2014 – 2022. Aug. 2017. https://www.alliedmarketresearch.com/IVF-in-vitro-fertilization-services-market

2 In-Vitro Fertilization (IVF) Market Analysis by Procedures, By Types of Cycles, By Instruments And Segment Forecasts to 2022. May 2016. https://www.researchandmarkets.com/reports/3736928/in-vitro-fertilization-ivf-market-analysis-by#relb0

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 30/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.